Key result
Bilateral cardiac sympathetic denervation achieves ~89% freedom from malignant ventricular arrhythmias.
Why the study?
Left cardiac sympathetic denervation is established for selected high-risk inherited arrhythmia syndromes, but evidence for an intended bilateral strategy in children and young adults remains limited.
Does intended bilateral cardiac sympathetic denervation prevent malignant ventricular arrhythmic events with acceptable safety in children and young adults with severe adrenergically mediated ventricular arrhythmias?
Observational (n=37)
No
Does intended bilateral cardiac sympathetic denervation prevent malignant ventricular arrhythmic events with acceptable safety in children and young adults with severe adrenergically mediated ventricular arrhythmias?
Intended upfront bilateral cardiac sympathetic denervation is technically feasible with low procedure-attributable morbidity (5.4%) and high 3-year malignant arrhythmia-free survival (89.4%) when used as an adjunct to medical and device therapy in high-risk children and young adults with severe adrenergically mediated ventricular arrhythmias.
Answers are grounded in this paper and cite their sources.
Supports adjunctive bilateral denervation in high-risk youth; leaves open need for randomized trials to confirm benefit.
Objective: Left cardiac sympathetic denervation is established for selected high-risk inherited arrhythmia syndromes, but evidence for an intended bilateral strategy in children and young adults remains limited. We evaluated the rationale, feasibility, safety, follow-up ascertainment, and outcomes of intended bilateral cardiac sympathetic denervation. Methods: Consecutive children and young adults undergoing intended bilateral cardiac sympathetic denervation between January 2015 and November 2025 were reviewed. The operation targeted the lower stellate component and upper thoracic sympathetic chain bilaterally, usually through single-port thoracoscopic access. Outcomes were obtained from specialist cardiology follow-up, electrocardiography, Holter monitoring, exercise testing when available, inpatient telemetry, device interrogation, and medication records. Results: Thirty-seven patients were operated. Mean age was 12.4 years. Bilateral denervation was completed in 36 patients; 1 underwent left-sided denervation only owing to intraoperative haemodynamic instability. Single-port access was used in 30 patients. There were no intraoperative deaths, unplanned full thoracotomy conversions, intercostal injuries, reoperations for surgical complications, or denervation-related permanent pacing. Procedure-attributable morbidity comprised one mild Horner syndrome and one self-limited axillary wound complaint. Among 36 patients with post-discharge follow-up, 32 remained free from the primary malignant ventricular arrhythmic endpoint. Estimated malignant ventricular arrhythmia-free survival was 95.8 per cent at 1 year and 89.4 per cent at 3 years. Conclusion: Intended bilateral cardiac sympathetic denervation was feasible and had low procedure-attributable morbidity in selected young patients. It should be interpreted as an adjunct to multidisciplinary arrhythmia care, not as a replacement for medication, device surveillance, or follow-up.
No takes yet. Share an insight, caveat, or question.
Uysal et al. (2026) conducted an observational in Severe adrenergically mediated ventricular arrhythmias (primarily CPVT and LQTS) (n=37). Intended bilateral cardiac sympathetic denervation was evaluated on Freedom from primary malignant ventricular arrhythmic endpoint (sustained VT/VF requiring intervention, appropriate ICD therapy, arrhythmic syncope, cardiac arrest, or arrhythmic death). Intended bilateral cardiac sympathetic denervation achieved 95.8% 1-year and 89.4% 3-year malignant ventricular arrhythmia-free survival with 88.9% (32/36) of patients remaining event-free.
Synapse has enriched 10 related papers. Consider them for comparative context: